Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
NCT04452591 · BOND-003 Phase 3Active, not recruiting
- Lead sponsor
- CG Oncology, Inc. (Industry)
- Enrollment
- 190 (estimated)
- Start date
- 27 Oct 2020
- Primary completion
- 16 Jun 2030 (estimated)
- Study completion
- 24 Dec 2031
- Last update posted
- 10 Jul 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Non randomized
- Intervention model
- Single group
- Masking
- None
- Arms
- 2
Interventions
- Cretostimogene Grenadenorepvec Biological
- n-dodecyl-B-D-maltoside Other
Conditions and primary outcome
- Non Muscle Invasive Bladder Cancer
- High-grade Ta/ T1 Papillary Disease Bladder Cancer
Primary outcome
Cohort C: (36 months); Cohort P: (36 months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
1 on PubMedIntravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.
The Lancet. Oncology · 2026 Aug
PubMed 42508433 (opens in a new tab)DOI 10.1016/S1470-2045(26)00194-4 (opens in a new tab)
Citations from PubMed, U.S. National Library of Medicine; abstracts are not stored. A publication lists this study’s NCT number and may be a review that cites many studies.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT04452591 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.